Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MG 1113A

Next Previous
Drug Profile

MG 1113A

Alternative Names: Anti-TFPI mAb - GC Pharma; Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody - GC Pharma; MG 1113; MG-1113A

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GC Pharma; Mogam Biotechnology Research Institute
  • Developer GC Biopharma
  • Class Antihaemorrhagics; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haemophilia

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Haemophilia in South Korea (SC, Injection)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Haemophilia(In volunteers) in South Korea (IV, Injection)
  • 01 Sep 2022 MG 1113A is in phase I clinical trial in Haemophilia (In volunteers) in South Korea (IV) as of August 2022 (NCT03855696)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top